Opiant Pharmaceuticals Inc (NASDAQ:OPNT) insider Phil Skolnick sold 1,821 shares of the firm’s stock in a transaction dated Monday, November 5th. The stock was sold at an average price of $18.01, for a total value of $32,796.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Phil Skolnick also recently made the following trade(s):
- On Thursday, October 4th, Phil Skolnick sold 4,778 shares of Opiant Pharmaceuticals stock. The stock was sold at an average price of $18.32, for a total value of $87,532.96.
NASDAQ OPNT opened at $17.36 on Thursday. Opiant Pharmaceuticals Inc has a 52 week low of $12.75 and a 52 week high of $36.77. The stock has a market capitalization of $49.01 million, a PE ratio of 5.90 and a beta of 0.34.
A hedge fund recently bought a new stake in Opiant Pharmaceuticals stock. Brasada Capital Management LP bought a new position in shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 15,000 shares of the technology company’s stock, valued at approximately $268,000. Brasada Capital Management LP owned approximately 0.50% of Opiant Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 4.51% of the company’s stock.
Several research firms have recently commented on OPNT. ValuEngine downgraded Opiant Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 28th. Cantor Fitzgerald set a $42.00 price objective on Opiant Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, September 28th.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Further Reading: How can investors find ex-dividend dates?
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.